In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: BioLife Solutions trades well above a high-confidence fair value estimate of $13.09, implying significant overvaluation by 55%. Key metrics, including DCF analysis with negative mid-values and zero profitability, contrast sharply with high liquidity and growth scores. Analyst targets near $34 suggest divergent views, while Monte Carlo shows minimal downside risk below current price.